Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice!
Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine
New workflow to provide unambiguous genetic results in a single assay, alleviating the need for time-consuming and costly follow-up tests
May 22, 2024 05:20 AM Eastern Daylight Time
OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
hxxps://www.businesswire.com/news/home/20240522912932/en/Oxford-Nanopore-Technologies-Collaborates-With-Twist-Bioscience-to-Launch-Pharmacogenomics-Beta-Programme-and-Advance-Personalised-Medicine/
Roll on 2027! ;)
See you in a few years then
From the annual report:
The Group remains strongly capitalised with adequate resources to implement our business plan to and through EBITDA breakeven in 2027 and deliver on the significant growth opportunity in front of us.
Would imagine so - ont is surely a bargain here at this price but as profits are years away, market has ignored it - probably sit here for years then rocket up one week if the company survives that long
IP Groups 10% holding could prove interesting as the weeks pass. It must have an exit strategy.....
BioMerieux bought in at 238p and they see value as joint partners in multiple projects. It's LSE that's holding it back as all the UK instos are focused elsewhere........for now. When, not if, the tide turns, this should gap-jump quickly.
Youre not alone but for people like me who bought a lot higher this has become a major disappointment of late
Bought in at 106.5 and reckon we will hit 120 by end week. Neck out.......
It needs a bid to come from a third party to start fireworks here. BioMerieux can't exceed 9.9% within 5 years of its £70m £2.38p a share investment last October. This restriction is suspended in the event of a third party offer. Interesting times as the window of opportunity opens next month.
BioMerieux must be favourites to acquire ONT at this level. Loads of mutually collaborative engagements and board welcomed c7% stake purchase in October with BM happy to increase another 2.5%. Protection built into 2021 IPO runs out shortly this year.
Open season for Oxford Nano as 3 year takeover lockout ends?
From its introduction to tomorrow's sellout symposium:
Exciting advancements in epigenetics are transforming clinical research! Discover how DNA methylation and histones discoveries, using nanopore technology, are aiding cancer research, anti-obesity drugs, & age-related disease
Conference Weds. This has been driven down upto this point and I'm happy to load up at my 106.5 paid. I consider it a perfect entry level now for a good short term and excellent medium term gain. Time will tell.
I expect updated information and progress in nanopore tech provided at Weds sellout conference to start rerate here. Darned sure bioMerieux and Illumina will be watching closely as will other big players. The former showed its hand last October by snapping up 7% and I expect a few others will start to position as the 3 year takeover lockout expires. Great British Company that could do with British institutional support before its swallowed by France or the USA.
Hopefully make it 3 in 3 months. Posted KNOS at 997 then VOD at 68 and onto ONT at 110. Two soared one pending.
The fact that all tickets have been sold out is an indicator of the huge interest in Oxford Nano and its groundbreaking tech. The 3 year takeover protection built into the IPO in 2021 ends this year and bioMerieux snapped up 7% in October. Interesting times ahead.
All they like to do now is short stocks, not support them.
No support from British funds to keep the momentum.... shameful. Hopefully a Stateside or French acquirer will show them just how cutting-edge and must-have this tech is.
All three factors needed to drive this back to 'infinity and beyond' are in play ..... plus we now have fomo!
120p looking achievable today given momentum....
Rocket - agree and it's still at a very silly price!
160p first resistance... this is going to rerate. Hood news coming from the US on inflation.
Buying pressure, volume and multie attempts to break the 114.2.......this time we succeed.